Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway

Clinical Cancer Research

Volumn 7, Issue 4, 2001, Pages 1010-1016

  Li, M ^a   Wu, X ^a   Xu, X C ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME C; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CELL DEATH; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APOPTOSIS; CASPASE 3; CASPASE 9; CASPASES; CELL SURVIVAL; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; CYTOCHROME C GROUP; ENZYME ACTIVATION; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MITOCHONDRIA; NITROBENZENES; POLY(ADP-RIBOSE) POLYMERASES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEINS; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 0034902004     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Cancer statistics, 2000
2. Aspirin use and reduced risk of fatal colon cancer
3. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
4. Aspirin and the risk of colorectal cancer in women
5. Colorectal cancer and nonsteroidal anti-inflammatory drugs
6. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin
7. Cyclooxygenase-2 inhibitors in tumorigenesis (part I)
8. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II)
9. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
10. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
11. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats
12. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
13. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis
14. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas
15. Cyclooxygenase-2 expression in human esophageal carcinoma
16. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs
17. Nonsteroidal anti-inflammatory drugs and cancer prevention
18. Aspirin, NSAIDS and colon cancer prevention: Mechanisms?
19. Apoptosis
20. Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation
21. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro
22. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic
23. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c
24. Cytochrome c release from mitochondria: All or nothing
25. Induction of mitochondrial permeability transition and cytochrome c release in the absence of caspase activation is insufficient for effective apoptosis in human leukemia cells
26. Mitochondria and apoptosis
27. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway
28. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells
29. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
30. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
31. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression
32. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells
33. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2
34. Aspirin induction of apoptosis in esophageal cancer: A potential for chemoprevention
35. The mitochondrial death/life regulator in apoptosis and necrosis
36. Mitochondrial control of cell death
37. The mitochondrion in cell death control: Certainties and incognita
38. Molecular characterization of mitochondrial apoptosis-inducing factor
39. Mitochondria as regulators of apoptosis: Doubt no more
40. Bcl-2 family: Life-or-death switch
41. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked
42. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
43. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
44. Suppression of intestinal polyposis in Apc δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
45. 15-LOX-1: A novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells
46. Intracellular unesterified arachidonic acid signals apoptosis
47. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs